These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://nicolasbzkt326522.dbblog.net/12286979/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide